- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Hypha Labs, Inc. Uplists to the OTCQB | 195 | ACCESSWIRE | OTCQB Listing Brings Transparency, Prestige and Beneficial Exposure LAS VEGAS, NV / ACCESSWIRE / September 16, 2024 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer in functional mushroom sciences, is pleased... ► Artikel lesen | |
| 20.08. | Hypha Labs, Inc.: Hypha Labs' Revolutionary Psilocybin Bioreactor Nominated for Best New Product of 2024 by Santa Monica Daily Press | 184 | ACCESSWIRE | LAS VEGAS, NV / ACCESSWIRE / August 20, 2024 / Hypha Labs, Inc. (OTC PINK:FUNI), a pioneer in functional mushroom sciences, is pleased to announce that the Company's proprietary bioreactor which allows... ► Artikel lesen | |
| 14.08. | Hypha Labs, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.08. | Digipath Name and Symbol Change Approved, Company Begins Trading as Hypha Labs, Inc. | 459 | ACCESSWIRE | LAS VEGAS, NV / ACCESSWIRE / August 13, 2024 / Hypha Labs, Inc. formerly (OTC PINK:DIGP), has been approved to commence trading as Hypha Labs, Inc. (OTC PINK:FUNI) on August 13, 2024. Hypha Labs has... ► Artikel lesen | |
| 31.07. | Hypha Labs, Inc.: Hypha Labs' Revolutionary Psilocybin Bioreactor Nominated for Best New Product of 2024 by Santa Monica Daily Press | 248 | ACCESSWIRE | LAS VEGAS, NV / ACCESSWIRE / July 31, 2024 / Hypha Labs, Inc. (OTC PINK:DIGP), a pioneer in functional mushroom sciences, is pleased to announce that the Company's proprietary bioreactor which allows... ► Artikel lesen | |
| 20.07. | Hypha Labs, Inc.: Hypha Laboratories Retains Integrity Media for Investor Relations and Corporate Communications | 891 | ACCESSWIRE | Veteran Agency Brings Twenty-Five Years of Experience and Relationships to Emerging Functional Mushroom Science CompanyLAS VEGAS, NV / ACCESSWIRE / July 19, 2024 / Hypha Labs, Inc. (OTC PINK:DIGP),... ► Artikel lesen | |
| 20.07. | Hypha Labs, Inc.: Hypha Laboratories Reveals New Patent Applications for Novel Artificial Intelligence Driven In-Home Mycelium Production | 925 | ACCESSWIRE | Company Intends to Bring First Functional Mushroom Producer to RetailLAS VEGAS, NV / ACCESSWIRE / July 19, 2024 / Hypha Labs, Inc. (OTC PINK:DIGP), a pioneer in functional mushroom sciences, is pleased... ► Artikel lesen | |
| 20.05. | Hypha Labs, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 20.05. | Hypha Labs, Inc.: Hypha Labs Announces New Patent Filing | 367 | ACCESSWIRE | New Patent Portfolio Unveiled Revolutionizing Psilocybin ProcessingLAS VEGAS, NV / ACCESSWIRE / May 20, 2024 / Hypha Labs, Inc. (OTC PINK:DIGP) Today marks a significant milestone in the realm of mycological... ► Artikel lesen | |
| 15.05. | Hypha Labs, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 1 | SEC Filings | ||
| 29.04. | Hypha Labs Names Chief Science Officer | 1 | Contract Pharma | ||
| 29.04. | Hypha Labs, Inc.: Hypha Labs Names Craig Ellins Chief Science Officer | 377 | ACCESSWIRE | LAS VEGAS, NV / ACCESSWIRE / April 29, 2024 / Hypha Labs, Inc. (OTC Pink:DIGP) has announced that it has made Craig Ellins its Chief Science Officer. Hypha Labs, Inc. changed its name from Digipath... ► Artikel lesen | |
| 22.04. | Digipath changes name to Hypha Labs | 1 | Seeking Alpha | ||
| 22.04. | DigiPath, Inc.: Digipath Enters Psilocybin Industry and Changes Name | 284 | ACCESSWIRE | LAS VEGAS, NV / ACCESSWIRE / April 22, 2024 / Hypha Labs, Inc. (OTC PINK:DIGP) has announced that it has changed its name from Digipath, Inc. after the sale of its cannabis lab assets. In a change of... ► Artikel lesen | |
| 18.04. | Hypha Labs, Inc. to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024 | 201 | ACCESSWIRE | LAS VEGAS, NV / ACCESSWIRE / March 18, 2024 / Hypha Labs, Inc. (OTC Pink:DIGP), short company description, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday... ► Artikel lesen | |
| 15.04. | Hypha Labs, Inc. - 8-K, Current Report | 1 | SEC Filings |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 112,10 | +0,99 % | Kurssprung bei Medigene! "Short-Squeeze" bei Evotec? BioNTech Aktie verkaufen? | Über 10 % konnte die Aktie von Medigene gestern zwischenzeitlich zulegen. Auslöser für den Kurssprung war, dass das Biotech-Unternehmen in den USA einen Meilenstein erreicht hat. Die FDA hat das Hauptprogramm... ► Artikel lesen | |
| QIAGEN | 41,615 | -0,34 % | Biotech Report: Evotec leichter, Qiagen behauptet | (shareribs.com) Frankfurt / New York 10.09.2024 - Biotech-Aktien zeigen sich am Dienstag uneinheitlich. Im deutschen Handel legen Qiagen und 4SC zu, Evotec geben nach. Auch an der Wall Street gibt es... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 25,760 | -12,68 % | PESG Research: PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch | With its focus on targeting well-defined subgroups by inhibiting SRC/YES1 kinases in Non Small-Cell Lung Cancer patients resistant to EGFR and ALK targeted therapies, Nuvectis Pharma's NXP900 could... ► Artikel lesen | |
| EVOTEC | 6,445 | +3,37 % | Evotec-Aktie: Kooperation bringt keinen Schwung | Die Evotec-Aktie hat trotz einer neuen Kooperation mit Scientist.com keinen signifikanten Kursanstieg erfahren und bleibt unter wichtigen charttechnischen Widerständen. Kurzfristig zeigte die Aktie... ► Artikel lesen | |
| NUVALENT | 107,50 | -4,10 % | Biopharma co Nuvalent slips after upsized $500 million stock offering priced | ||
| ADMA BIOLOGICS | 18,960 | +4,29 % | ADMA Biologics to join S&P SmallCap 600 index | ||
| MODERNA | 66,66 | +7,26 % | Guter Tag für Moderna-Aktionäre: Aktienkurs steigt deutlich (71,8335 €) | Die Aktie von Moderna zählt heute zu den großen Gewinnern an der Börse. Das Wertpapier steigt deutlich. Zu den besten Performern am Aktienmarkt zählt zur Stunde der Anteilsschein von Moderna. Im Vergleich... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 20,920 | +1,70 % | CSL And Arcturus Therapeutics Announce Japanese Approval For Updated Self-amplifying MRNA COVID-19 Vaccine | CANBERA (dpa-AFX) - Australian biotechnology company CSL Ltd. (CSL.AX, CSLLY.PK) and sa-mRNA pioneer Arcturus Therapeutics, announced Friday that Japan's Ministry of Health, Labor and Welfare... ► Artikel lesen | |
| IMMUNEERING | 3,080 | +8,26 % | Pre-market Movers: Tenon Medical, Vision Marine Technologies, SMX, Singular Genomics Systems, Immuneering | SAN JOSE (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.00 A.M. ET).In the Green Tenon Medical, Inc. (TNON) is up over 350% at $19.80.
Vision... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,920 | +4,22 % | Looking Into Recursion Pharmaceuticals' Recent Short Interest | ||
| AVIDITY BIOSCIENCES | 42,280 | +1,34 % | Unveiling 7 Analyst Insights On Avidity Biosciences | ||
| PHATHOM PHARMACEUTICALS | 18,500 | -1,96 % | Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update | Over 122,000 prescriptions for VOQUEZNA® products written by healthcare providers, launch to date, a 184% increase since last quarterly reportNet revenues of $7.3 million reported for the second quarter... ► Artikel lesen | |
| DYNE THERAPEUTICS | 34,870 | +1,34 % | Dyne Therapeutics Reports Positive Data From Phase 1/2 DELIVER Trial Of DYNE-251 In DMD | WASHINGTON (dpa-AFX) - Tuesday, Dyne Therapeutics, Inc. (DYN) revealed new clinical findings from its Phase 1/2 DELIVER trial of DYNE-251 for patients with Duchenne muscular dystrophy also known... ► Artikel lesen | |
| INSTIL BIO | 57,68 | -9,86 % | Instil Bio: Waschechter Tenbagger für den NBC! | Die Erfolgsgeschichte des exklusiven No Brainer Clubs (NBC) setzt sich fort: Mit Instil Bio hat der NBC erneut einen absoluten Volltreffer gelandet, der Mitgliedern je nach Einstiegszeitpunkt +736 bis... ► Artikel lesen | |
| BEAM THERAPEUTICS | 26,250 | +2,34 % | Deep Dive Into Beam Therapeutics Stock: Analyst Perspectives (6 Ratings) |
HYPHA LABS INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HYPHA LABS INC finden Sie auf Wallstreet Online.
